Seaport Therapeutics, founded by Karuna Therapeutics leaders, secures a $100M Series A funding round for developing new mental disorder treatments.
Seaport Therapeutics, founded by Karuna Therapeutics leaders, launches with a $100M Series A funding round to develop new treatments for mental disorders. The Boston-based company will focus on neuropsychiatric medicines, led by CEO Daphne Zohar and Steven Paul as chairman. The funding round was co-led by ARCH Venture Partners and Sofinnova Investments with participation from Third Rock Ventures and PureTech Health.
April 09, 2024
7 Articles